Small molecule therapeutics for treatment of neuropsychiatric disorders
Glial cell line-derived neurotropic factor (GDNF) is an essential protein for the growth, development, and plasticity of dopaminergic and motor neurons. Elevated GDNF levels are associated with decreased risk for neuropsychiatric disorders, including addiction and depression. This technology describes a class of organic molecules designed to specifically elevate GDNF levels in the brain. By selectively inducing GDNF, the small molecules identified in this technology can be potentially used as a treatment for alcohol abuse, depression, Parkinson's disease, and other neuropsychiatric disorders.
These small molecules specifically induce GDNF production without interfering with other signaling pathways in the brainReduced risk of side effectsPatent Information:Patent Pending (WO/2013/028999)Patent Pending (US 20150056699)Tech Ventures Reference: IR M11-026
Potential treatment for alcohol, drug, and other addictionsPotential treatment for depressionPotential treatment for Parkinson's diseasePotential treatment for neuropathic painResearch tool for studying GDNF expression
None
美國
